133 related articles for article (PubMed ID: 36410129)
1. Development of simple and rapid method for Emicizumab quantification by LC-MS/MS in human plasma.
Josset L; Hodin S; Delinger S; Marin C; Dargaud Y; Delavenne X
J Pharm Biomed Anal; 2023 Jan; 223():115163. PubMed ID: 36410129
[TBL] [Abstract][Full Text] [Related]
2. Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study.
Donners AAMT; Gerencsér L; van der Elst KCM; Egberts TCG; de Maat MPM; Huisman A; Urbanus RT; El Amrani M
Res Pract Thromb Haemost; 2022 May; 6(4):e12725. PubMed ID: 35702589
[TBL] [Abstract][Full Text] [Related]
3. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
Bowyer A; Kitchen S; Maclean R
Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits.
Truffot A; Jourdil JF; Seitz-Polski B; Malvezzi P; Brglez V; Stanke-Labesque F; Gautier-Veyret E
Clin Biochem; 2021 Jan; 87():60-66. PubMed ID: 33096054
[TBL] [Abstract][Full Text] [Related]
5. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
[TBL] [Abstract][Full Text] [Related]
6. A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry.
Amrani ME; Gerencser L; Huitema ADR; Hack CE; van Luin M; van der Elst KCM
J Chromatogr A; 2021 Oct; 1655():462489. PubMed ID: 34509691
[TBL] [Abstract][Full Text] [Related]
7. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry.
Heudi O; Barteau S; Zimmer D; Schmidt J; Bill K; Lehmann N; Bauer C; Kretz O
Anal Chem; 2008 Jun; 80(11):4200-7. PubMed ID: 18465883
[TBL] [Abstract][Full Text] [Related]
8. Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA.
Millet A; Khoudour N; Bros P; Lebert D; Picard G; Machon C; Goldwasser F; Blanchet B; Guitton J
Talanta; 2021 Mar; 224():121889. PubMed ID: 33379098
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a stable isotope labeled (SIL) peptide and an extended SIL peptide as internal standards to track digestion variability of an unstable signature peptide during quantification of a cancer biomarker, human osteopontin, from plasma using capillary microflow LC-MS/MS.
Faria M; Halquist MS; Yuan M; Mylott W; Jenkins RG; Karnes HT
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Sep; 1001():156-68. PubMed ID: 26279007
[TBL] [Abstract][Full Text] [Related]
10. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A.
Josset L; Leuci A; Janbain M; De-Wreede A; Desage S; Lienhart A; Bin V; Lambert D; Delavenne X; Dargaud Y
J Thromb Haemost; 2024 Apr; ():. PubMed ID: 38583717
[TBL] [Abstract][Full Text] [Related]
11. A new reliable, transposable and cost-effective assay for absolute quantification of total plasmatic bevacizumab by LC-MS/MS in human plasma comparing two internal standard calibration approaches.
Legeron R; Xuereb F; Chaignepain S; Gadeau AP; Claverol S; Dupuy JW; Djabarouti S; Couffinhal T; Schmitter JM; Breilh D
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Dec; 1070():43-53. PubMed ID: 29111437
[TBL] [Abstract][Full Text] [Related]
12. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?
Jourdil JF; Lebert D; Gautier-Veyret E; Lemaitre F; Bonaz B; Picard G; Tonini J; Stanke-Labesque F
Anal Bioanal Chem; 2017 Feb; 409(5):1195-1205. PubMed ID: 27826630
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
[TBL] [Abstract][Full Text] [Related]
14. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
[TBL] [Abstract][Full Text] [Related]
15. Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantification of Olorofim (F901318), a Novel Antifungal Drug, in Human Plasma and Serum.
Müller C; Fietz C; Koehler P; Sibley G; Nforbugwe ACA; Streichert T; Wiesen MHJ
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150474
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
[TBL] [Abstract][Full Text] [Related]
17. Approximation of emicizumab plasma levels in emergency situations. A practical approach.
Pekrul I; Pfrepper C; Calatzis G; Giebl A; Siegemund A; Grützner S; Spannagl M
Haemophilia; 2021 Mar; 27(2):e214-e220. PubMed ID: 33522651
[TBL] [Abstract][Full Text] [Related]
18. Two validated liquid chromatography-mass spectrometry methods with different pretreatments for the quantification of an anti-CD47 monoclonal antibody in rat and cynomolgus monkey serum compared with an electrochemiluminescence method.
Gao Y; Zhang D; Yang C; Duan X; Li X; Zhong D
J Pharm Biomed Anal; 2019 Oct; 175():112792. PubMed ID: 31377653
[TBL] [Abstract][Full Text] [Related]
19. Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma.
Tripodi A; Chantarangkul V; Novembrino C; Scalambrino E; Boscolo-Anzoletti M; Clerici M; Rossi F; Peyvandi F
Clin Chem Lab Med; 2020 Sep; 59(2):365-371. PubMed ID: 32892172
[TBL] [Abstract][Full Text] [Related]
20. Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS.
Chiu HH; Liao HW; Shao YY; Lu YS; Lin CH; Tsai IL; Kuo CH
Anal Chim Acta; 2018 Aug; 1019():93-102. PubMed ID: 29625688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
